Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages

  Pavlovic, Milica ^a   Arnal Estapé, Anna ^a   Rojo, Federico ^b,c   Bellmunt, Anna ^a   Tarragona, Maria ^a   Guiu, Marc ^a   Planet, Evarist ^a   Garcia Albéniz, Xabier ^a,j   Morales, Mónica ^a   Urosevic, Jelena ^a   Gawrzak, Sylwia ^a   Rovira, Ana ^b   Prat, Aleix ⁱ   Nonell, Lara ^b   Lluch, Ana ^d,e   Jean Mairet, Joël ^f   Coleman, Robert ^g   Albanell, Joan ^b,h   Gomis, Roger R ^a,k  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c 28400 Madrid   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e Valencia Central University   (Spain)

^f Inbiomotion SL   (Spain)

^g Cancer Research Centre   (United Kingdom)

^h UNIVERSITAT POMPEU FABRA   (Spain)

ⁱ VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^k INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KETAMINE; TRANSCRIPTION FACTOR MAF; XYLAZINE; MAF PROTEIN, HUMAN; TRANSCRIPTION FACTOR C MAF; TUMOR MARKER;

4T1 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE METASTASIS; BREAST CANCER; BREAST CANCER CELL LINE; CANCER RECURRENCE; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC SUSCEPTIBILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MAF GENE; MCF-7 CELL LINE; METASTATIC BREAST CANCER; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; OSTEOBLAST; OSTEOCLASTOGENESIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; RISK ASSESSMENT; T-47D CELL LINE; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ZR-75 CELL LINE; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; BREAST TUMOR; COPY NUMBER VARIATION; GENE EXPRESSION REGULATION; INCIDENCE; METABOLISM; ODDS RATIO; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY; TUMOR CELL LINE; UPREGULATION; XENOGRAFT;

ANIMALS; BIOMARKERS, TUMOR; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MICE; MICE, INBRED BALB C; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-MAF; UP-REGULATION;

EID: 84955336478     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv256     Document Type: Article

References (42)

1. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277.
2. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284.
3. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
4. Tarragona M, Pavlovic M, Arnal-Estape A, et al. Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J Biol Chem. 2012;287(25):21346–21355.
5. Hu G, Chong RA, Yang Q, et al. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009;15(1):9–20.
6. Arnal-Estape A, Tarragona M, Morales M, et al. HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPss isoforms. Cancer Res. 2010;70(23):9927–9936.
7. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res. 2007;35(Database issue):D760–D765.
8. van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.
9. Lu X, Mu E, Wei Y, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701–714.
10. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003;100(19):10954–10959.
11. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549.
12. Bos PD, Zhang XH, Nadal C, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005–1009.
13. Cheung WK, Zhao M, Liu Z, et al. Control of alveolar differentiation by the lineage transcription factors GATA6 and HOPX inhibits lung adenocarcinoma metastasis. Cancer Cell. 2013;23(6):725–738.
14. Vanharanta S, Shu W, Brenet F, et al. Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nat Med. 2013;19(1):50–56.
15. Rojo F, Garcia-Parra J, Zazo S, et al. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2011;23(5):1156–1164.
16. CancerGenomeAtlasNetwork. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
17. Morito N, Yoh K, Fujioka Y, et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res. 2006;66(2):812–819.
18. Murakami YI, Yatabe Y, Sakaguchi T, et al. c-Maf expression in angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2007;31(11):1695–1702.
19. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2):191–199.
20. Eychene A, Rocques N, Pouponnot C. A new MAFia in cancer. Nat Rev Cancer. 2008;8(9):683–693.
21. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16(1):67–78.
22. Guise TA, Yin JJ, Thomas RJ, et al. Parathyroid hormone-related protein (PTHrP)-(1–139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone. 2002;30(5):670–676.
23. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401–419.
24. Guise TA, Kozlow WM, Heras-Herzig A, et al. Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer. 2005;5(Suppl2):S46–S53.
25. MacLean HE, Kim JI, Glimcher MJ, et al. Absence of transcription factor c-maf causes abnormal terminal differentiation of hypertrophic chondrocytes during endochondral bone development. Dev Biol. 2003;262(1):51–63.
26. Lanske B, Karaplis AC, Lee K, et al. PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science. 1996;273(5275):663–666.
27. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007;8(5):341–352.
28. Eckhardt BL, Francis PA, Parker BS, et al. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012;11(6):479–497.
29. Takagaki K, Takashima T, Onoda N, et al. Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients. Exp Ther Med. 2012;3(6):963–968.
30. Henderson MA, Danks JA, Slavin JL, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res. 2006;66(4):2250–2256.
31. Yerushalmi R, Woods R, Kennecke H, et al. Patterns of relapse in breast cancer: changes over time. Breast Cancer Res Treat. 2010;120(3):753–759.
32. Chang NS, Doherty J, Ensign A, et al. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol. 2003;66(8):1347–1354.
33. Hansen LL, Yilmaz M, Overgaard J, et al. Allelic loss of 16q23.2–24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res. 1998;58(10):2166–2169.
34. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441–451.
35. Harkonen P, Kyllonen AP, Nordling S, et al. Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer. Prostate. 2005;62(3):267–274.
36. Myllykangas S, Himberg J, Bohling T, et al. DNA copy number amplification profiling of human neoplasms. Oncogene. 2006;25(55):7324–7332.
37. Coquelle A, Pipiras E, Toledo F, et al. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell. 1997;89(2):215–225.
38. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396–1405.
39. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631–641.
40. NCT01077154. US National Library of Medicine. ClinicalTrials.gov.
41. Coleman RE. Bone cancer in 2011: Prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011;9(2):76–78.
42. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101(21):1446–1452.